ERBB2 and cancer: YAP inhibition via verteporfin shows potential in reducing oncogenic properties and overcoming immune evasion in HR cells, providing a strong rationale for further exploration of the ROR2-YAP/TEAD axis as a therapeutic target for HR HER2-positive cancers.